Trials / Completed
CompletedNCT01146522
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
A Multiple-dose, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCQ908 in Patients With Severe Hypertriglyceridemia and Chylomicronemia (Phenotypes I and V)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess safety, tolerability, and effect of LCQ908 on blood lipids in patients with severe hypertriglyceridemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCQ908 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-06-17
- Last updated
- 2020-12-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01146522. Inclusion in this directory is not an endorsement.